COURSE AND OUTCOME OF TREATMENT RESISTANT DEPRESSION: A ONE-YEAR NATURALISTIC FOLLOW-UP
Settore scientifico disciplinare
MED/25
Corso di studi
NEUROSCIENZE E SCIENZE ENDOCRINOMETABOLICHE
Relatori
tutor Prof. Mauri, Mauro
Parole chiave
psychiatry
treatment resistant depression
Data inizio appello
15/12/2014
Consultabilità
Completa
Riassunto
Most recent epidemiological studies point out that depression is one of the most common diseases among general population and it is recognized as a major public health problem. The primary goal of depression treatment consists of the complete resolution of symptoms and thus in the total healing. Clinical experience and literature data indicate that, with current treatments, only a small percentage of patients achieves a full symptom remission. The results of the STAR*D, which focused on the effectiveness of treatments, showed that one-third of depressed patients will never reach complete recovery even after multiple drug trials 5. . From these data emerges that treatment resistance is quite common among patients with Major Depressive Disorders and accounts for an important part of human suffering and social burden caused by depression 6-7 . In the present study we examined a sample of depressed inpatients during a one-year naturalistic follow-up. The aims of the study were: 1) to investigate the demographic and clinical characteristics associated with Treatment Resistant Depression (TRD); 2) to evaluate the prospective course and outcome of illness over a one-year naturalistic follow-up; 3) to compare the clinical and demographic variables of treatment-resistant patients with a group of patients matched by sex and diagnosis, who adequately responded to the drug treatment A consecutive series of subjects, aged 18-70 years, hospitalized in our centre, with a Major Unipolar or Bipolar Depression diagnosis recruited from January 2008 to January 2009 were included in the analysis (TRd: Treatment resistant depressives) . Patients with a primary diagnosis of Unipolar MDD or BPD; stage I of Thase & Rush criteria for resistance to treatment and a baseline Montgomery-Asberg Depression Scale (MADRS) 149 score > 21 were included in the study and were enrolled in the 12 months naturalistic follow up . Afterwards, we screened a sample of 47 outpatients matched by sex with the same inclusion and exclusion criteria, except that of treatment resistance, in fact they began antidepressant treatment not later than two months before with positive response.(Rd: Responder depressives) In our study TRD population is mainly composed by middle aged female, married, with high level of education. TRD patients report a personal history of treatment resistance and personal and familiar history of suicide attempts. A bipolar diathesis may represent an important clinical characteristics of TRD patients, too. Treatment resistance appears mainly related to melancholic episodes, duration of the current episode, number of previous depressive episodes and hospitalizations, and suicide risk. Somatic comorbidity (specifically cardiovascular diseases), Axis I disorder comorbidity, particularly anxiety disorders (Panic Disorder) may be highly frequent in TRD population. During the follow up year the majority of the TRD patients examined (63.8%) have a remission and about 20% of the sample have a recovery. Although TRD is a common clinical occurrence, a greater consensus is required regarding the definition and the operational criteria for staging response and resistance to antidepressant treatments. Predictive factors must be identified to recognize patients who are more likely to respond to antidepressant trials. Pharmacogenomic studies are also needed to assist in identifying biological predictive factors.